MusaYilmazMD

PubMed

• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
  Ravandi, F., Pierce, S., Sasaki, K., Kadia, T., DiNardo, C., Yilmaz, M., Short, N., Jabbour, E., Patel, K., Loghavi, S., Borthakur, G., Kantarjian, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
• 1 citations
  Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
  Bataller, A., Bazinet, A., DiNardo, C., Maiti, A., Borthakur, G., Daver, N., Short, N., Jabbour, E., Issa, G., Pemmaraju, N., Yilmaz, M., Montalban-Bravo, G., Takahash...> ;Blood Advances. 2024 Feb 27
• Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
  Jen, W., Rausch, C., Alvarado, Y., McCue, D., Ravandi, F., Sasaki, K., DiNardo, C., Kadia, T., Yilmaz, M., Borthakur, G., Kantarjian, H., McCue, D.> ;Leukemia & Lymphoma. 2024 Mar 1
• 2 citations
  Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
  Farhad Ravandi, Asad Bashey, James Foran, Wendy Stock, Raya Mawad, Nicholas Short, Musa Yilmaz, Hagop Kantarjian, Olatoyosi Odenike, Anand Patel, Raman Garcha, William...> ;Blood Advances. 2023 Nov 14
• Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia.
  Musa Yilmaz, Naval Daver> ;The Lancet. Haematology. 2023 Aug 1
• 1 citations
  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
  Fadi G Haddad, Koji Sasaki, Aram Bidikian, Ghayas C Issa, Tapan Kadia, Nitin Jain, Yesid Alvarado, Nicholas J Short, Naveen Pemmaraju, Sanam Loghavi, Keyur P Patel, Ra...> ;American Journal of Hematology. 2023 Oct 1
• 3 citations
  A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and c...
  Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C Issa, Samuel I Dara, Mahesh Basyal, Li Li, K...> ;Blood Cancer Journal. 2023 Jun 29
• 1 citations
  Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
  Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, Uday Popat, Alex Bataller, Koji Sasaki, Courtney D DiNardo, Naval Daver, Musa Yilmaz, Hussein A Abbas, Nicholas J S...> ;American Journal of Hematology. 2023 Sep 1
• 11 citations
  Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
  Nicholas J Short, Elias Jabbour, Walid Macaron, Farhad Ravandi, Nitin Jain, Rashmi Kanagal-Shamanna, Keyur P Patel, Sanam Loghavi, Fadi G Haddad, Musa Yilmaz, Ghayas C...> ;American Journal of Hematology. 2023 Aug 1
• 11 citations
  Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
  Hagop Kantarjian, Fadi G Haddad, Nitin Jain, Koji Sasaki, Nicholas J Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Ye...> ;Journal of Hematology & Oncology. 2023 May 2
• 6 citations
  Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
  Nicholas J Short, Faustine Ong, Farhad Ravandi, Graciela Nogueras-Gonzalez, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Marina Konopleva, Gautam Borthakur, Betul O...> ;Blood Advances. 2023 Jul 25
• 8 citations
  Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
  Alexandre Bazinet, Tapan Kadia, Nicholas J Short, Gautam Borthakur, Sa A Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, ...> ;Blood Advances. 2023 Jul 11
• 7 citations
  The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
  Elias J Jabbour, Koji Sasaki, Fadi G Haddad, Ghayas C Issa, Guillermo Garcia-Manero, Tapan M Kadia, Nitin Jain, Musa Yilmaz, Courtney D DiNardo, Keyur P Patel, Rashmi ...> ;American Journal of Hematology. 2023 Apr 1
• 67 citations
  Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
  Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria ...> ;Nature Medicine. 2023 Jan 1
• 10 citations
  Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
  Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D DiNardo, Tapan M Kadia, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Musa Yilmaz,...> ;Blood Advances. 2023 Mar 28
• 17 citations
  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 tr...
  Elias Jabbour, Nicholas J Short, Nitin Jain, Philip A Thompson, Tapan M Kadia, Alessandra Ferrajoli, Xuelin Huang, Musa Yilmaz, Yesid Alvarado, Keyur P Patel, Guillerm...> ;The Lancet. Haematology. 2022 Dec 1
• 8 citations
  Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
  Daniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, Gautam Borthakur, Guillermo Montalban-Bravo, Naval Daver, Courtney Dinardo, Nicholas J Short, Musa Yilmaz, Naveen P...> ;American Journal of Hematology. 2022 Dec 1
• 6 citations
  Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
  Sangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, Wei Qiao, Farhad Ravandi, Marina Konopleva, Tapan Kadia, Kapil Bhalla, Elias Jabbour, Ghayas C Issa, Walid Maca...> ;American Journal of Hematology. 2022 Dec 1
• 3 citations
  Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context ofalterations and venetoclax treatment.
  Hussein A Abbas, Edward Ayoub, Hanxiao Sun, Rashmi Kanagal-Shamanna, Nicholas J Short, Ghayas Issa, Musa Yilmaz, Sherry Pierce, Daniel Rivera, Brent Cham, Shane Wing, ...> ;Leukemia & Lymphoma. 2022 Dec 1
• 10 citations
  Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
  Zehra Narlı Özdemir, Necati Alp Kılıçaslan, Musa Yılmaz, Ahmet Emre Eşkazan> ;International Journal of Hematology. 2023 Jan 1
• 32 citations
  Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalati...
  Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, Guillermo Montalban-Bravo, Maro Ohanian, Kelly Chien, Tapan Kadia, Koichi Takahashi, Lucia Masarova, Nicholas Shor...> ;The Lancet. Haematology. 2022 Oct 1
• Join now to see all

Abstracts/Posters

• Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019